FDA
-
-
-
-
-
-
-
Zymeworks authorizes $125 million share repurchase program
-
-
-
-
-
-
-
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
-
-
-
-
-
-
-
Zymeworks receives FDA fast track designation for ovarian cancer drug
-
-
-
-
-
-
-
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
-
-
-
-
-
-
-
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
-
-
-
-
-
-
-
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
-
328,513 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

